Payment overview · 2025
General Payments
$604.63
29 reported records · 17 companies
Healthcare provider profile · identity verified
Christopher Morris, DO
Allopathic & Osteopathic Physicians|Family Medicine · SURPRISE, AZ · NPI 1417446618
Verified facts
What the public records show
CMS Open Payments records show Christopher Morris, DO received $604.63 in general payments during 2025 across 29 reported records.
Philips North America LLC accounted for 10.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $61.29 | 10.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.97 | 9.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.91 | 9.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.81 | 9.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.36 | 9.0% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $49.30 | 8.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.10 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.32 | 5.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.69 | 4.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.45 | 4.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.44 | 4.0% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $21.85 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.56 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.19 | 3.3% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $19.27 | 3.2% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.24 | 3.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.88 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $604.63 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.97 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $34.77 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.42 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $26.52 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 203 | 98 |
| Lisinopril | Lisinopril | 112 | 51 |
| Losartan Potassium | Losartan Potassium | 97 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 54 |
| Metformin Hcl | Metformin Hcl | 70 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 60 |
| Omeprazole | Omeprazole | 63 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 27 |
| Gabapentin | Gabapentin | 55 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 33 |
| Prednisone | Prednisone | 49 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 25 |
| Ozempic | Semaglutide | 41 | 14 |
| Sertraline Hcl | Sertraline Hcl | 38 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 12 |
| Azithromycin | Azithromycin | 36 | 35 |
| Lorazepam | Lorazepam | 28 | 12 |
| Tramadol Hcl | Tramadol Hcl | 27 | 18 |
| Trazodone Hcl | Trazodone Hcl | 27 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | 14 |
| Montelukast Sodium | Montelukast Sodium | 25 | 17 |
| Famotidine | Famotidine | 24 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | 17 |
| Metformin Hcl Er | Metformin Hcl | 23 | 12 |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Jardiance | Empagliflozin | 22 | 11 |
| Furosemide | Furosemide | 21 | 15 |
| Simvastatin | Simvastatin | 21 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 13 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | 12 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Eliquis | Apixaban | 17 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $604.63 · 29 records | Philips North America LLC | ABRYSVO, AIRSUPRA, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, BARRIGEL, BREZTRI, COMIRNATY, CREON, CRYSVITA, EVENITY, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, KRYSTEXXA, Kerendia, Korlym, LINZESS, Leqembi, MCOT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tlando, UBRELVY, VRAYLAR, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error